The 21 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 205.00, with a high estimate of 430.00 and a low estimate of 96.00. The median estimate represents a +63.48% increase from the last price of 125.40.
The current consensus among 23 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.61
Reporting Date Aug 10
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.